Website: integralmolecular.com   |   LinkedIn: linkedin.com/company/integral-molecular

Drugging the Undruggable

How Integral Molecular became the go-to partner for antibodies against the hardest membrane protein targets

At a glance

  • Company: Integral Molecular (integralmolecular.com)
  • Headquarters: uCity Square, Philadelphia, PA
  • Focus: Antibody discovery and characterization for membrane proteins: GPCRs, ion channels, transporters, and immuno-oncology and viral targets
  • Business model: Discovery partnerships, specificity and characterization services, target discovery collaborations, and antibody licensing
  • Working with PSG on: Sales and business development scaling

Built for the targets everyone else avoids

Many of medicine’s most valuable drug targets sit in the cell membrane, and many of them are notoriously hard to make antibodies against. Multipass membrane proteins express poorly, depend on the membrane for their structure, show small extracellular regions, and often look nearly identical in humans and rodents.

Integral Molecular has built its entire business around solving that problem. Grown from a two-person startup at Philadelphia’s University City Science Center into a multi-facility research company, it is now known as a leader in membrane protein antibody discovery.

The MPS Antibody Discovery platform

Integral Molecular’s MPS platform is purpose-built for multipass membrane proteins. It combines proprietary technologies to generate strong immune responses against conserved targets and to screen deeply for rare, functional antibodies:

  • Lipoparticles: patented technology that presents membrane proteins in their native structure
  • Multiple immunization hosts: proprietary humanized chicken antibody technology (hCAT), plus fully human transgenic mice through a partnership with Alloy Therapeutics
  • B-cell cloning: rapid isolation of rare antibodies
  • Functional assays: GPCR signaling, ion channel activation, and T-cell receptor activation

The result is preclinical-ready leads with picomolar affinity, specificity across the membrane proteome, agonist or antagonist activity, and cross-reactivity with animal orthologs. Partners such as Seismic Therapeutic have licensed antibodies discovered on the platform.

The Membrane Proteome Array: de-risking every antibody

Off-target binding is a major cause of safety failures in drug development. Integral Molecular’s Membrane Proteome Array (MPA) tackles it head-on.

  • About 6,000 human membrane proteins, each expressed in live human cells and covering about 94% of the membrane proteome, including nearly all GPCRs, ion channels, and transporters
  • Specificity profiling that flags off-target liabilities early, from full lead panels to single preclinical candidates
  • Target discovery and de-orphaning, used in collaborations with partners such as Daiichi Sankyo and Totient
  • Peer-reviewed impact: Integral Molecular’s research in mAbs found that as many as one-third of antibody-based drugs show nonspecific binding
  • Regulatory recognition: accepted into FDA’s ISTAND Drug Development Tools pilot program

Protecting public health, too

Integral Molecular’s epitope mapping technology helps researchers understand immune responses to viruses including SARS-CoV-2, Ebola, Zika, and dengue. An $8 million NIAID contract extends that work to emerging threats such as Rift Valley Fever, Crimean-Congo Hemorrhagic Fever, and Enterovirus D68.